CIK 0001023024
- Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 582301143
- Phone
- +1 609-759-1810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 400 shares at $53.92 ($21,568)
- 4 Open-market sale SVP & CFO sold 7,500 shares at $55.79 ($418,425)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 250 shares at $56.24 ($14,060)
- 4 Planned sale SVP, CHIEF HR OFFICER sold 1,000 shares at $60.00 ($60,000)
- 4 Open-market sale PRESIDENT & CEO sold 33,481 shares at an average $57.99 ($1,941,442)
- 4 Shares withheld for taxes SVP, HEAD - ESTABLISHED BRANDS gave up 867 shares (to pay taxes)
- 4 Open-market sale HEAD OF RARE DISEASE sold 6,500 shares at $57.70 ($375,050)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 250 shares at $61.36 ($15,340)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 250 shares at $57.19 ($14,298)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 250 shares at $56.82 ($14,205)
- 4 Shares withheld for taxes SVP, CHIEF HR OFFICER gave up 1,486 shares (to pay taxes)
- 4 Shares withheld for taxes PRESIDENT & CEO gave up 3,646 shares (to pay taxes)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 250 shares at $59.62 ($14,905)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 2,743 shares at $62.00 ($170,066)
- 4 Shares withheld for taxes SR. VP, GENERAL COUNSEL & SEC. gave up 1,743 shares (to pay taxes)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 47,257 shares at an average $63.73 ($3,011,592)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 250 shares at $64.91 ($16,228)
- 4 Planned sale SVP - CORP. DEV. & STRATEGY sold 20,000 shares at $63.44 ($1,268,800)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 20,000 shares at $58.90 ($1,178,000)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 30,000 shares at an average $60.59 ($1,817,663)
Page 8 of 42 · 834 filings